Healthcare / Medical Care FacilitiesThailand
$84.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $131.7M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
21.7x
↑EV/EBITDA
6.3x
↓ROE
16.8%
↑Gross Margin
36.2%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.2%
FCF CAGR
-5.9%
FCF margin
11.9%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.14B · net income $152.2M · FCF $135.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.14B | $1.14B | $1.02B | $1.18B | $1.06B |
| Net Income | $152.2M | $152.2M | $140.6M | $105.6M | $81.0M |
| EBITDA | $238.6M | $238.6M | $216.2M | $173.8M | $149.5M |
| EPS | — | — | 7.26 | 5.45 | 4.18 |
| Gross Margin | 36.2% | 36.2% | 36.3% | 38.7% | 36.3% |
| Operating Margin | 16.1% | 16.1% | 16.4% | 10.9% | 9.7% |
| Net Margin | 13.4% | 13.4% | 13.8% | 9.0% | 7.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| Current Ratio | 4.82 | 4.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $135.1M | $135.1M | $131.7M | $80.4M | $162.1M |
| Returns | |||||
| ROE | 16.8% | 16.8% | 17.5% | 15.0% | 13.2% |
| Valuation | |||||
| P/E | 21.71 | 21.71 | 13.09 | 17.43 | 22.31 |
| EV/EBITDA | 6.28 | 6.28 | 7.87 | 9.74 | 11.05 |
| P/B | 1.80 | 1.80 | 2.29 | 2.61 | 2.95 |
| Growth & Yield | |||||
| Revenue Growth | 11.2% | 11.2% | -13.4% | 11.0% | — |
| EPS Growth | — | — | 33.2% | 30.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
7.26 → n/d
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.